Articolul precedent |
Articolul urmator |
387 5 |
Ultima descărcare din IBN: 2024-04-08 18:51 |
SM ISO690:2012 NOROC, Cristina, CIOBANU, Victor. Antiphospholipid syndrome and pregnancy. In: Cercetarea în biomedicină și sănătate: calitate, excelență și performanță, Ed. 1, 20-22 octombrie 2021, Chişinău. Chișinău, Republica Moldova: 2021, p. 406. ISBN 978-9975-82-223-7 (PDF).. |
EXPORT metadate: Google Scholar Crossref CERIF DataCite Dublin Core |
Cercetarea în biomedicină și sănătate: calitate, excelență și performanță 2021 | ||||||
Conferința "Cercetarea în biomedicină și sănătate: calitate, excelență și performanță" 1, Chişinău, Moldova, 20-22 octombrie 2021 | ||||||
|
||||||
Pag. 406-406 | ||||||
|
||||||
Descarcă PDF | ||||||
Rezumat | ||||||
Background. Antiphospholipid Syndrome (APS) is an autoimmune thrombophilic condition. Recurrent miscarriage, early delivery, intrauterine growth restriction, preeclampsia, HELLP syndrome, arterial or venous thrombosis and placental insufficiency are the most severe APS-related pregnancy complications. Objective of the study. To understand the clinical features and pathophysiology of APS, the principles of management of APS in pregnancy, and learn about the key points of prepregnancy assessment and counselling. Material and Methods. This work is an up-to-date view of the main pathophysiological, clinical, diagnostic and therapeutic advances in Antiphospholipid Syndrome. Results. Obstetric complications are the hallmark of antiphospholipid syndrome. AnAceastă tiphospholipid antibodies (lupus anticoagulant (LAC), anticardiolipin (aCL) antibody, and anti-beta-2glycoprotein I antibody) promote activation of endothelial cells, monocytes and platelets, causing an overproduction of tissue factor and thromboxane A2. Complement activation might have a central pathogenetic role. These factors, associated with the typical changes in the hemostatic system during normal pregnancy, result in a hypercoagulable state. This is responsible of thrombosis that is presumed to provoke many of the pregnancy complications associated with APS. Conclusion. Screening for thrombophilia patients in the risk group and administering treatment depending on the titer of antiphospholipid antibodies is essential to prevent pregnancy complications related to antiphospholipid syndrome. |
||||||
Cuvinte-cheie Antiphospholipid, pregnancy, hypercoagulability, thromboprophylaxis, sindromul antifosfolipidic, sarcina, hipercoagulabilitate, tromboprofilaxie |
||||||
|